Arvinas Inc.

Last updated September 27, 2026

Organization details

Legal name
Arvinas Inc.
Former names
Arvinas Holding Company, LLC
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
New Haven
Headquarters state / province
Connecticut
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ARVN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001655759
EIN
47-2566120

Board of directors

Chief executives

Randy Teel · President and CEO
Since February 2026
John G. Houston · President and CEO
Until February 2026 · Former

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

9 of this board's directors also sit on 15 other boards.

Network of Arvinas Inc.'s board connections Autolus Therapeutics plc American Depositary Share Autolus Therapeutics p... Black Diamond Therapeutics Inc. Black Diamond Therapeu... BlackBerry Limited BlackBerry Limited CRISPR Therapeutics AG CRISPR Therapeutics AG CVS Health Corporation CVS Health Corporation Globus Medical Inc. Globus Medical Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... InnovAge Holding Corp. InnovAge Holding Corp. Johnson Controls International plc Johnson Controls Inter... Neurocrine Biosciences Inc. Neurocrine Biosciences... NextCure Inc. NextCure Inc. Quanterix Corporation Quanterix Corporation Syndax Pharmaceuticals Inc. Syndax Pharmaceuticals... Werewolf Therapeutics Inc. Werewolf Therapeutics... Zevra Therapeutics Inc. Zevra Therapeutics Inc... Alsup Laurie Smaldone Alsup Laurie Smaldon... Briggs Morrison Briggs Morrison Edward Moore Kennedy Jr. Edward Moore Kennedy... Everett Cunningham Everett Cunningham John D. Young John D. Young John G. Houston John G. Houston Leslie Norwalk V Leslie Norwalk V Linda Bain Linda Bain Wendy L. Dixon Wendy L. Dixon Arvinas Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$268,000
1 purchase by 1 insider
Sold, last 12 months
$1,421,299
23 sales by 6 insiders
Date Insider Transaction Shares Price Value
Jun 24, 2026 Alsup Laurie Smaldone Director Grant or award +15,527 — —
Jun 24, 2026 Leslie Norwalk V Director Grant or award +15,527 — —
Jun 24, 2026 Briggs Morrison Director Grant or award +15,527 — —
Jun 24, 2026 Edward Moore Kennedy Jr. Director Grant or award +15,527 — —
Jun 24, 2026 Everett Cunningham Director Grant or award +15,527 — —
Jun 24, 2026 Linda Bain Director Grant or award +15,527 — —
Jun 24, 2026 Andrew Saik Officer (Chief Financial Officer) Open-market sale −5,696 $8.16 $46,479
Jun 17, 2026 Cacace Angela M Officer (Chief Scientific Officer) Open-market sale −2,576 $7.60 $19,578
May 21, 2026 Randy Teel Director, Officer (President and CEO) Open-market sale −2,209 $9.04 $19,969
May 11, 2026 Andrew Saik Officer (Chief Financial Officer) Open-market sale −11,139 $9.94 $110,722
May 11, 2026 Loomis David K Officer (VP, Chief Accounting Officer) Open-market sale −1,919 $9.94 $19,075
May 11, 2026 Cacace Angela M Officer (Chief Scientific Officer) Open-market sale −9,657 $9.94 $95,991
May 11, 2026 Berkowitz Noah Officer (Chief Medical Officer) Open-market sale −11,108 $9.94 $110,414
May 11, 2026 Randy Teel Director, Officer (President and CEO) Open-market sale −9,657 $9.94 $95,991
Mar 18, 2026 Berkowitz Noah Officer (Chief Medical Officer) Open-market sale −6,435 $11.10 $71,429

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.